BGNE Stock Cash Flow Statements

BeiGene Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

BeiGene Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31

operating activities:
net income	94,320,000	1,270,000	-151,881,000	-121,350,000	-120,405,000	-251,150,000	-367,553,000	215,413,000	-381,137,000	-348,431,000	-445,335,000	-552,757,000	-571,449,000	-434,274,000	-585,653,000	-413,855,000	-480,341,000	66,495,000	-472,649,000	-426,617,000	-336,318,000	-364,939,000	-387,895,000	-308,660,000	-85,954,000	-168,069,000	-266,710,000	-144,492,000	-157,715,000	-105,116,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization expense	35,614,000	32,804,000	50,246,000	71,292,000	24,931,000	25,293,000	23,819,000	21,510,000	22,335,000	20,011,000	18,016,000	16,201,000	15,461,000	16,600,000	13,121,000	12,177,000	11,527,000	9,632,000	7,828,000	8,344,000	7,867,000	7,750,000	7,484,000	4,022,000	3,695,000	3,416,000	3,363,000	2,445,000	2,336,000	2,244,000
share-based compensation expenses	150,809,000	95,478,000		114,697,000	130,637,000	88,667,000		96,004,000	103,371,000	75,322,000		78,176,000	81,305,000	65,555,000		67,077,000	64,791,000	45,833,000		50,297,000	45,468,000	38,255,000		36,818,000	32,602,000	26,392,000	25,958,000	25,132,000	18,641,000	17,396,000					2,779,000	1,285,000	2,614,000
acquired in-process research and development							31,800,000				48,665,000				30,000,000	0	45,000,000	8,500,000	20,000,000	46,500,000	0	43,000,000	20,000,000	0	20,000,000	29,000,000	60,000,000	0	0	10,000,000
gain on deconsolidation of a subsidiary					0	-3,735,000													0
amortization of research and development cost share liability	-25,757,000	-19,812,000	-21,612,000	-16,575,000	-21,903,000	-13,136,000	-16,725,000	-15,900,000	-5,271,000	-17,398,000	-26,013,000	-24,806,000	-23,764,000	-21,819,000	-29,640,000	-28,944,000	-26,972,000	-26,930,000	-28,690,000	-30,056,000	-27,606,000	-27,634,000
other items	2,759,000	12,369,000	-353,000	6,103,000	4,565,000	848,000	-6,820,000	55,000	192,000	575,000	1,285,000	1,402,000	2,816,000	3,544,000	5,791,000	6,507,000	5,949,000	5,263,000	5,490,000	2,007,000	242,000	-1,105,000
changes in operating assets and liabilities:
accounts receivable	-41,503,000	-31,866,000	-125,699,000	-29,848,000	-93,871,000	-80,025,000	-44,795,000	-11,588,000	4,564,000	-136,487,000	19,395,000	-22,713,000	14,876,000	292,554,000	-353,845,000	-55,836,000	10,318,000	-23,656,000	-134,000	1,403,000	5,858,000	3,236,000	-14,966,000	2,196,000	868,000	-17,920,000	-3,684,000	-4,201,000	-9,686,000	5,943,000
inventories	2,187,000	3,987,000	-79,384,000	23,837,000	1,315,000	-37,264,000	-88,577,000	1,227,000	-40,571,000	-13,027,000	18,943,000	-43,999,000	-28,631,000	-3,002,000	-91,647,000	-33,392,000	-44,613,000	16,319,000	-51,934,000	-2,291,000	-4,459,000	-222,000	8,959,000	11,536,000	-35,908,000	3,102,000	3,457,000	-13,377,000	1,176,000	3,432,000
other assets	-75,053,000	29,737,000	35,621,000	41,738,000	-27,832,000	-4,401,000	29,718,000	13,029,000	19,781,000	-50,408,000	-33,607,000	-1,990,000	49,268,000	-16,953,000	-14,190,000	-15,734,000
accounts payable	-4,284,000	-31,568,000	107,961,000	11,344,000	-44,108,000	46,300,000	-9,882,000	64,044,000	-10,089,000	-22,589,000	-8,555,000	34,565,000	4,662,000	-35,024,000	32,384,000	30,182,000	30,620,000	-73,178,000	73,856,000	-12,872,000	56,301,000	-21,450,000	10,375,000	-29,582,000	41,795,000	-20,364,000	17,893,000	-4,731,000	28,795,000	-18,487,000		8,178,000	4,768,000	8,474,000
accrued expenses and other payables	127,985,000	-52,360,000	56,716,000	82,894,000	51,053,000	-79,309,000	130,022,000	58,171,000	30,599,000	-38,681,000	43,999,000	-17,897,000	93,567,000	-74,042,000	139,225,000	-869,000	35,698,000	-34,010,000	66,821,000	71,401,000	28,696,000	15,775,000	30,536,000	29,959,000	12,325,000	-8,790,000	24,259,000	845,000	19,324,000	6,115,000		22,241,000	-2,036,000	2,166,000	7,489,000	2,649,000	3,222,000
other liabilities	-3,979,000	4,043,000	-14,233,000	241,000	-186,000	-660,000	532,000	-33,000	-109,000	197,000	-1,376,000	2,281,000	-400,000	-1,714,000	-6,058,000	249,000
net cash from operating activities	263,598,000	44,082,000	75,160,000	188,369,000	-95,588,000	-308,572,000	-221,638,000	-78,150,000	-293,888,000	-563,777,000	-318,191,000	-561,906,000	-379,959,000	-236,563,000	-507,839,000	-495,713,000	-420,266,000	125,095,000	-332,334,000	-346,241,000	-262,942,000	-341,944,000	-267,181,000	-265,012,000	-46,101,000	-171,975,000	-193,894,000	-132,185,000	-117,137,000	-104,501,000	93,749,000	6,600,000
capex	-43,826,000	-56,407,000	0	-133,655,000	-109,950,000	-156,578,000	0	-157,882,000	-121,470,000	-125,585,000	0	-108,655,000	-50,290,000	-45,131,000	0	-67,043,000	-38,531,000	-42,389,000	0	-28,681,000	-32,605,000	-21,533,000	0	-30,873,000	-21,447,000	-21,828,000	-23,254,000	-26,720,000	-10,613,000	-9,696,000	0	-18,560,000
free cash flows	219,772,000	-12,325,000	75,160,000	54,714,000	-205,538,000	-465,150,000	-221,638,000	-236,032,000	-415,358,000	-689,362,000	-318,191,000	-670,561,000	-430,249,000	-281,694,000	-507,839,000	-562,756,000	-458,797,000	82,706,000	-332,334,000	-374,922,000	-295,547,000	-363,477,000	-267,181,000	-295,885,000	-67,548,000	-193,803,000	-217,148,000	-158,905,000	-127,750,000	-114,197,000	93,749,000	-11,960,000
investing activities:
purchases of property, plant and equipment	-43,826,000	-56,407,000		-133,655,000	-109,950,000	-156,578,000		-157,882,000	-121,470,000	-125,585,000		-108,655,000	-50,290,000	-45,131,000		-67,043,000	-38,531,000	-42,389,000		-28,681,000	-32,605,000	-21,533,000		-30,873,000	-21,447,000	-21,828,000
purchase of intangible asset				0	0	-4,674,000
proceeds from sale or maturity of investments	0	1,800,000		0	0	2,655,000		19,000	190,538,000	376,962,000		301,370,000	720,000,000	331,028,000		760,876,000	890,515,000	1,107,000,000	778,467,000	975,366,000	740,499,000	256,743,000		384,537,000	456,893,000	710,598,000
purchase of in-process research and development	0	-60,000,000	0	0	0	-31,800,000	0				-48,665,000	-20,000,000	0	-75,000,000	0	0	0	-8,500,000	-20,000,000	-46,500,000	0	-43,000,000	-20,000,000	0	-20,000,000	-29,000,000	-60,000,000	0	0	-10,000,000
other investing activities	-2,779,000	-7,334,000	17,881,000	-227,000	-1,082,000	-19,434,000				-9,250,000						0
net cash from investing activities	-66,605,000	-121,941,000	-93,605,000	-133,882,000	-111,032,000	-209,831,000	-62,584,000	-186,275,000	67,800,000	241,063,000	38,536,000	169,484,000	658,710,000	210,393,000	109,110,000	-11,995,000	251,596,000	291,948,000	-86,925,000	-1,536,577,000	-429,895,000	-1,114,969,000	-23,892,000	213,630,000	192,009,000	172,416,000	213,243,000			-394,352,000	-68,242,000			43,543,000			40,343,000
financing activities:
proceeds from long-term loan			0	0	0	9,053,000	0	6,731,000			0				0	6,019,000	155,000	10,664,000							7,009,000	36,695,000	0	0							7,640,000
repayment of long-term loan	-12,584,000	-4,215,000	-10,450,000	-3,561,000	-10,441,000	-3,579,000	-5,228,000			-1,457,000																	0
proceeds from short-term loans	141,521,000	80,000,000	543,858,000	0	182,384,000	142,028,000	498,916,000	768,000			150,000,000	96,188,000	17,586,000	50,000,000	262,993,000	30,867,000	41,588,000	71,001,000
repayment of short-term loans	-102,861,000	-172,921,000	-546,726,000	0			-150,000,000	-93,002,000	-16,574,000	-50,000,000	-271,653,000	-30,023,000	-42,258,000	-73,147,000	-281,525,000
payments of withholding taxes from share-based awards
proceeds from option exercises and employee share purchase plan	33,144,000	63,359,000	8,795,000	16,223,000	5,564,000	14,791,000	3,360,000	17,183,000	3,580,000	31,589,000	11,287,000	16,705,000	7,092,000	11,880,000	10,570,000	46,591,000	9,847,000	25,754,000	17,271,000	47,632,000	16,569,000	11,629,000	26,617,000	9,745,000	4,373,000	6,269,000
other financing activities			0	0
net cash from financing activities	35,025,000	-33,777,000	-4,523,000	12,662,000	23,017,000	162,293,000	347,048,000	-76,782,000	166,080,000	-19,868,000	-110,366,000	120,242,000	-17,580,000	-11,267,000	3,384,654,000	109,207,000	35,631,000	107,419,000	325,658,000	1,994,007,000	80,993,000	2,802,168,000	2,198,000	25,136,000	15,382,000	42,964,000	8,803,000	871,250,000	46,583,000	763,901,000	3,048,000	339,708,000	145,067,000	2,533,000	7,640,000	4,521,000	170,049,000
effect of foreign exchange rate changes	23,477,000	3,480,000	-51,713,000	28,348,000	-5,902,000	-22,438,000	42,266,000	525,000	-62,184,000	11,311,000	64,546,000	-62,717,000	-80,212,000	9,000,000	7,266,000	1,512,000	9,318,000	-4,061,000	13,891,000	8,627,000	1,925,000	-6,212,000	8,827,000	-15,607,000	-6,997,000	4,265,000	1,765,000	-7,644,000	-1,661,000	3,444,000		2,522,000					86,000
net increase in cash, cash equivalents, and restricted cash													180,959,000	-28,437,000	2,993,191,000	-396,989,000	-123,721,000	520,401,000	-79,710,000	119,816,000	-609,919,000	1,339,043,000	-280,048,000	-41,853,000	154,293,000	47,670,000	29,917,000	240,785,000	-38,083,000	268,492,000
cash, cash equivalents, and restricted cash at beginning of period	0	2,638,747,000		0	0	3,185,984,000		0	0	3,875,037,000		0	0	4,382,887,000		0	0	1,390,005,000		0	0	620,775,000		0	0	740,713,000		0
cash, cash equivalents, and restricted cash at end of period	255,495,000	2,530,591,000		95,497,000	-189,505,000	2,807,436,000		-340,682,000	-122,192,000	3,543,766,000		-334,897,000	180,959,000	4,354,450,000		-396,989,000	-123,721,000	1,910,406,000		119,816,000	-609,919,000	1,959,818,000		-41,853,000	154,293,000	788,383,000		240,785,000
supplemental cash flow information:
cash and cash equivalents	239,645,000	2,516,411,000	-74,523,000	109,278,000	-200,715,000	2,793,370,000	104,464,000	-343,032,000	-128,276,000	3,538,644,000	-327,568,000	-334,005,000	183,975,000	4,347,162,000	2,992,368,000	-393,138,000	-125,371,000	1,901,819,000	-82,520,000	119,456,000	-612,087,000	1,957,101,000		-62,797,000	154,456,000	764,492,000		205,065,000	-52,214,000	490,634,000
short-term restricted cash	4,469,000	11,333,000	28,000	-13,871,000	11,710,000	11,445,000	-75,000	1,855,000	9,534,000	159,000	5,000	-142,000	3,000	330,000	-2,000	20,000	5,000	305,000	12,000	12,000	1,000	282,000
long-term restricted cash	11,381,000	2,847,000	-186,000	90,000	-500,000	2,621,000	703,000	495,000	-3,450,000	4,963,000	2,088,000	-750,000	-3,019,000	6,958,000	825,000	-3,871,000	1,645,000	8,282,000	2,798,000	348,000	2,167,000	2,435,000
income taxes paid	67,712,000	9,321,000	14,652,000	9,142,000	43,146,000	2,490,000	13,487,000	9,987,000	24,913,000	7,616,000	4,494,000	570,000	23,700,000	736,000	481,000	687,000	14,049,000	478,000	0	1,346,000	8,719,000	531,000		1,077,000	7,514,000	360,000		309,000	11,513,000	329,000		683,000	670,000	76,000	0	0	25,000
interest expense paid	11,812,000	12,206,000		14,014,000	12,708,000	11,440,000																			1,202,000	888,000		879,000	336,000	331,000		322,000	313,000	305,000	268,000	134,000	108,000
supplemental non-cash information:
capital expenditures included in accounts payable and accrued expenses	-2,087,000	60,010,000		-40,247,000	15,091,000	100,473,000		12,207,000	31,391,000	64,013,000
rou assets obtained in exchange for new operating lease liabilities	2,482,000	15,659,000
increase in equity investment from deconsolidation of a subsidiary				0	0	40,798,000
net decrease in cash, cash equivalents, and restricted cash		-108,156,000	-74,681,000	95,497,000	-189,505,000	-378,548,000		-340,682,000	-122,192,000	-331,271,000
cash flows from operating activities:
share-based compensation expense																																13,327,000	7,082,000	5,992,000
unrealized losses on long-term investments
deferred income tax expense
gain on bms termination settlement							0
deferred revenue			156,000	261,000			0	-183,010,000	-39,511,000	-33,066,000	-38,996,000	-36,083,000	-37,061,000	-39,676,000	282,805,000	-13,979,000	-11,368,000	150,245,000					0	0	-25,744,000	-2,238,000	-3,383,000	-2,234,000	-1,703,000	-1,739,000
cash flows from investing activities:
purchases of property and equipment																											-23,254,000	-26,720,000	-10,613,000	-9,696,000		-18,560,000
proceeds from sale or maturity of short-term investments
purchase of intangible assets																											-332,000
purchase of long-term investments
cash flows from financing activities:
cash, cash equivalents, and restricted cash, beginning of year
cash, cash equivalents, and restricted cash, end of year
supplemental cash flow disclosures:
interest paid									4,998,000	5,017,000	5,304,000	6,966,000	6,282,000	6,617,000	6,569,000	9,131,000	7,340,000	6,927,000	2,553,000	38,223,000	2,218,000	1,136,000
supplemental non-cash activities:
accruals for capital expenditures
purchase of in-process research and development included in accounts payable
acquired intangible asset included in accounts payable
unrealized losses (gains) on long-term investments
purchases of short-term investments
proceeds from public offering, net of cost
proceeds from sale of ordinary shares, net of cost															0				0	2,069,610,000	0	2,162,407,000
unrealized losses on equity investments								10,095,000	2,009,000	169,000			6,555,000	16,974,000
deferred income tax benefits								750,000	-51,000	36,000		-7,170,000	12,836,000	-5,286,000	-2,677,000	-26,097,000	-60,000	-12,251,000	-19,045,000	-7,702,000	-854,000	-206,000	4,102,000	-11,878,000	-473,000	-983,000	-13,150,000	-386,000	-4,323,000	-4,090,000		-1,812,000
purchases of investments								-3,999,000	-10,518,000	-1,064,000		-3,231,000	-11,000,000	-504,000		-705,828,000	-592,888,000	-764,163,000	-810,703,000	-2,436,762,000	-1,135,764,000	-1,307,179,000	-318,475,000	-140,034,000	-223,437,000	-487,354,000	-519,176,000	-917,588,000	-566,698,000	-632,224,000
unrealized losses (gains) on equity investments											5,583,000
proceeds from research and development cost share liability																			0	0	0	616,834,000
payment to acquire joint venture (jv) minority interest
acquisitions of equipment included in accounts payable												-11,366,000	-4,060,000	62,736,000	11,300,000	13,012,000	-2,021,000	30,906,000	11,836,000	1,964,000	2,550,000	26,412,000		-6,672,000	3,465,000	32,462,000		4,014,000	4,366,000	3,640,000		109,000	-831,000	2,204,000	241,000	-13,000	91,000
acquired in-process research and development included in accrued expenses																0
unrealized gains on equity investments															9,534,000
capital contribution from noncontrolling interest																							0	0								0
prepayment to acquire joint venture ("jv") minority interest
unrealized losses/(gains) on equity investments
repayment of short-term loan																																0
unrealized gains on equity method investments																		3,327,000		1,290,000
prepaid expenses and other current assets																		-11,453,000	-12,587,000	1,649,000	-18,515,000	-36,075,000	14,310,000	270,000	-6,265,000	-8,270,000	-12,000,000	-6,633,000	-13,911,000	-13,758,000		-5,931,000
other non-current assets																		-6,495,000	15,291,000	-8,608,000	5,338,000	-2,710,000	-5,475,000	-5,014,000	-81,000	-10,212,000	-31,729,000	-4,805,000	-1,612,000	-2,082,000		-496,000
tax payable																		7,149,000	14,591,000	-9,266,000	-9,086,000	6,080,000	4,393,000	6,886,000	-4,682,000	969,000	4,252,000	398,000	-8,738,000	733,000		-1,180,000	536,000	1,766,000	126,000	135,000	33,000
operating lease liabilities																		1,215,000	-5,414,000	-2,094,000	-3,511,000	10,917,000	7,129,000	1,689,000	-1,167,000	1,550,000
other long-term liabilities																		-910,000	1,426,000	-26,778,000	1,207,000	-1,256,000	9,982,000	-1,521,000	-871,000	892,000	4,052,000	13,107,000	-1,130,000	933,000		-379,000	230,000	329,000	82,000
deconsolidation of a subsidiary																			0
payment for asset acquisition, net of cash acquired
proceeds from public offering
proceeds from public offering and hk ipo
payment to acquire joint venture ("jv") minority interest
proceeds from loans
repayment of loans
note
changes in operating assets and liabilities adjusted through accumulated deficit																												0	0	2,291,000
operating lease right-of-use assets																				2,258,000	1,525,000	-8,990,000	-7,181,000	-699,000	-2,016,000	-1,588,000
proceeds from long-term loans
repayment of long-term loans
attributable to beigene, ltd.
ordinary shares
shares
balance at december 31, 2019
issuance of ordinary shares in connection with collaboration
use of shares reserved for share option exercises
exercise of options, espp and release of restricted share units
share-based compensation
other comprehensive income
balance at march 31, 2020
exercise of options, espp issuances and release of rsus
use of shares reserved for share option exercises and rsu releases
other comprehensive loss
balance at june 30, 2020
proceeds from issuance of ordinary shares, net of cost
exercise of options, espp and release of rsus
issuance of shares reserved for share option exercises
balance at september 30, 2020
balance at december 31, 2018
balance at march 31, 2019
contributions from shareholders
gain on deconsolidation of entity
non-cash interest expense																					2,534,000	2,572,000	2,570,000	1,717,000	1,901,000	1,858,000	1,856,000	1,849,000	2,103,000	2,012,000		2,564,000
deconsolidation of entity
proceeds from long-term bank loan
proceeds from short-term bank loan																					14,899,000	11,298,000
issuance of shares reserved for share option exercises and rsu releases
balance at june 30, 2019
benefit from doubtful accounts																						2,022,000
unrealized gain on equity securities																						-6,964,000
payment for the acquisition of land use right
cash acquired in business combination, net of cash paid
proceeds from sale or maturity of available-for-sale securities																													611,443,000	257,568,000		84,028,000	96,287,000	65,613,000
proceeds from public offering, net of underwriter discount																													0	758,001,000
payment of public offering cost																													0	-414,000
proceeds from public offering and hk ipo, net of underwriter discount
payment of public offering and hk ipo costs
proceeds from long-term bank loans																							0
repayment of long-term bank loans
proceeds from short-term loan																																0	0	2,470,000
proceeds from shareholder loan																																0
realized gain on available-for-sale securities
non-cash amortization of bond discount																								-51,000	-1,244,000	-2,408,000	-3,593,000
unbilled receivable																								0	6,114,000	2,498,000	-3,734,000	7,824,000	11,160,000	-7,555,000
prepayment of assets acquisition
proceeds from follow-on public offering, net of underwriter discount
payment of follow-on public offering cost
proceeds from hk ipo and global follow-on public offering
payment of hk ipo and global follow-on public offering costs
repayment of long-term bank loan
restricted cash, current																								-296,000	-333,000	14,900,000
restricted cash, non-current																								21,240,000	170,000	8,991,000
disposal gain on available-for-sale securities																									-996,000	-810,000
changes in fair value of financial instruments																																			0	0	1,514,000
loss on disposal of property and equipment																											125,000							7,000
disposal (gain) loss on available-for-sale securities
proceeds from disposal of property and equipment
proceeds from exercise of warrants and rental deferral option
proceeds from option exercises																											8,803,000	10,277,000	4,268,000	6,314,000
discount provided on sale of ordinary shares for business combination
other non-cash income																													-1,854,000	-482,000
net cash from (provided by) investing activities
restricted cash																													14,131,000	17,460,000
non-cash activities:
cash, cash equivalents, and restricted cash at beginning of year																														239,602,000
cash, cash equivalents, and restricted cash at end of year																														508,094,000
net effect of foreign exchange rate changes
net increase in cash and cash equivalents																															31,092,000	-52,496,000	163,256,000	10,236,000	27,448,000	-150,422,000	190,637,000
operating activities
net income /
adjustments to reconcile net income/(loss) to net cash from operating activities:
other non-cash expenses
advances from customers
investing activities
purchase of available-for-sale securities																																-436,419,000
investment in time deposits
financing activities
proceeds from exercise of warrants and options																																		63,000
cash and cash equivalents at beginning of period																																0	0	87,514,000	0	0	17,869,000
cash and cash equivalents at end of period																																-52,496,000	163,256,000	97,750,000	27,448,000	-150,422,000	208,506,000
conversion of senior promissory note																																			0	0	14,693,000
conversion of deferred rental																																			0	0	980,000
conversion of convertible preferred shares																																			0	0	176,084,000
exercise of warrants and options
initial public offering costs accrued in accrued expenses and other payables																																			0
depreciation expense																																	540,000	864,000
payment for the acquisition of land use rights
net cash from / (used in) investing activities
proceeds from issuance of ordinary shares, net of underwriter discount
payment of initial public offering cost
proceeds from employee option exercises
(gain)/loss on sale of available-for-sale securities
interest expense																																			25,000	0	93,000
payment for land auction deposit
depreciation expenses																																			505,000	492,000	439,000
disposal loss on available-for-sale securities																																			137,000	228,000	712,000
proceeds from disposal of available-for-sale securities																																			67,761,000	46,900,000	43,646,000
proceeds from issuance of ordinary shares, net of initial public offering costs																																			0	0	167,931,000
proceeds from issuance of preferred shares
payment of convertible preferred shares issuance cost
conversion of warrant and option liabilities																																			0	0	3,687,000
proceeds from exercise of warrants																																				0	2,118,000
deferred rental
initial public offering costs accrued for in accrued expenses and other payables																																					166,000
gain on debt extinguishment
acquisition of non-controlling interest
proceeds from issuance of convertible promissory notes
proceeds from issuance of secured guaranteed convertible promissory note
proceeds from issuance of convertible preferred shares
proceeds from exercise of share options
proceeds due to related parties
repayment to related party
repayment of subordinated convertible promissory note, convertible promissory notes and secured guaranteed convertible promissory note
repayment of due to related parties

We provide you with 20 years of cash flow statements for BeiGene stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BeiGene stock. Explore the full financial landscape of BeiGene stock with our expertly curated income statements.

The information provided in this report about BeiGene stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.